Shifting paradigms of nontuberculous mycobacteria in cystic fibrosis

Respiratory Research

Table 1 Studies reporting the prevalence of nontuberculous mycobacteria in cystic fibrosis populations

Study	Study year	Location	Design	Included CF patients	NTM cases	NTM revalence	% MABSC	% MAC
Boxerbaum B.	1980	OH, USA	Prospective	430	8	1.8	75*	0
Smith MJ et al. [21]	1984	UK	Prospective	223	4	1.8	25*	0
Hjelte L et al. [22]	1990	Sweden	Prospective	54	5	9.2	0	60
Kilby JM et al. [23]	1992	NC, USA	Prospective	87	17	19.5	29*	76
Aitken ML et al. [24]	1993	WA, USA	Prospective	64	8	12.5	0	88
Hjelt K et al. [25]	1994	Denmark	Prospective	185	7	3.8	71*	29
Sermet-Gaudelus I et al. [26]	1996-99	France	Prospective	296	29	9.8	52	21
Fauroux B et al. [27]	1997	France	Prospective	106	7	6.6	43*	0
Mussaffi H et al. [28]	1997-02	Israel	Retrospective	139	12	8.6	67§	25§
Esther CR Jr et al. [29]	2000-07	NC, USA	Registry	1,216	166	13.7	41	59
Pierre-Audigier C et al. [30]	2000	France	Prospective	385	31	8.1	42	23
Oliver A et al. [19]	2000	Spain	Prospective	37	6	16.2	50*	33
Radhakrishnan et al. [31]	2004	Canada	Prospective	98	6	6.1	33	67
Levy I et al. [32]	2001-03	Israel	Cross-sectional	186	42	22.6	31	14
Olivier KN et al. [33]	2002	USA	Prospective	986	128	13.0	20	72
Roux AL et al. [34]	2004	France	Prospective	1,582	104	6.6	48	22
Valenza et al. [35]	2006	Germany	Prospective	60	8	13.3	50	50
Chalermskulrat W et al. [36]	2006	OH, USA	Retrospective	132	26	19.7	46	50
Binder AM et al. [37]	2011	USA	Registry	5,403	191	3.5	36	64

* = M. chelonae reported, but is here included as MABSC due to historical changes in taxonomy. § = percentage based on 6 chronic NTM cases.

ISSN: 1465-993X